Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have received an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $44.10.

A number of equities research analysts recently issued reports on OLMA shares. JPMorgan Chase & Co. upped their price target on shares of Olema Pharmaceuticals from $55.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, March 18th. Wall Street Zen raised shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, April 27th. Oppenheimer reissued an “outperform” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Wolfe Research started coverage on shares of Olema Pharmaceuticals in a research note on Friday, March 27th. They issued a “peer perform” rating on the stock. Finally, TD Cowen reissued a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th.

Institutional Investors Weigh In On Olema Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in OLMA. EverSource Wealth Advisors LLC raised its stake in shares of Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after acquiring an additional 1,232 shares during the period. Torren Management LLC purchased a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at $44,000. Russell Investments Group Ltd. purchased a new stake in shares of Olema Pharmaceuticals in the third quarter valued at $53,000. American Century Companies Inc. purchased a new stake in shares of Olema Pharmaceuticals in the second quarter valued at $54,000. Finally, Creative Planning purchased a new stake in shares of Olema Pharmaceuticals in the second quarter valued at $83,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $9.88 on Thursday. The company has a market cap of $863.02 million, a price-to-earnings ratio of -4.89 and a beta of 1.98. The firm’s fifty day moving average is $13.86 and its 200 day moving average is $20.43. The company has a quick ratio of 10.88, a current ratio of 10.88 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals has a 52-week low of $3.90 and a 52-week high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52). Sell-side analysts forecast that Olema Pharmaceuticals will post -2.16 EPS for the current fiscal year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.